Supernus Pharmaceuticals, Inc. (SUPN) Stock

Supernus Pharmaceuticals, Inc., based in Rockville, Maryland, is a dynamic biopharmaceutical company dedicated to advancing treatments for central nervous system (CNS) disorders across the United States. The company specializes in developing and commercializing a diverse portfolio of products tailored to address critical needs in neurology and psychiatry.

Supernus' current commercial offerings include Trokendi XR, an extended-release formulation of topiramate used for treating epilepsy and migraine prophylaxis. Another key product, Oxtellar XR, offers extended-release oxcarbazepine for monotherapy in managing partial onset epilepsy seizures in adults and children aged 6 to 17.

In addition to these established therapies, Supernus Pharmaceuticals markets Qelbree, a selective norepinephrine reuptake inhibitor designed to treat attention-deficit hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17. The company also offers a range of other medications addressing various aspects of Parkinson's disease, including APOKYN for acute intermittent hypomobility treatment and XADAGO for managing off episodes.

Supernus' robust pipeline includes promising candidates such as SPN-812, completed Phase III trials for ADHD treatment; SPN-830, a late-stage drug/device combination targeting off episodes in Parkinson's disease; SPN-817, in Phase I trials for severe epilepsy; and SPN-820, in Phase II trials for resistant depression. The company is also advancing SPN-443 and SPN-446 through preclinical stages for potential CNS applications.

Founded in 2005, Supernus Pharmaceuticals continues to innovate and expand its therapeutic offerings, collaborating closely with pharmaceutical wholesalers, specialty pharmacies, and distributors to ensure widespread access to its transformative treatments. With a commitment to advancing CNS healthcare, Supernus remains at the forefront of developing solutions that improve the lives of patients affected by neurological and psychiatric conditions.